Syndivia develops site-specific antibody-drug conjugates (ADCs) using its proprietary GeminiMab™ technology, which enables optimal drug-to-antibody ratios by conjugating payloads at the hinge region of native antibodies. This approach enhances antitumor efficacy and safety for cancer patients by improving tumor penetration and minimizing payload immunogenicity.
Funding
$2.3M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Traditional antibody-drug conjugate (ADC) development faces challenges in achieving optimal drug-to-antibody ratios (DAR) and site-specific conjugation, potentially leading to reduced efficacy and increased toxicity. Existing conjugation methods often require enzymatic modification or result in heterogeneous DAR distributions, impacting the therapeutic window of ADCs.
Solution
Syndivia's GeminiMab™ technology enables site-specific ADC development by conjugating payloads at the hinge region of native antibodies, ensuring optimal DAR. The GeminiMab™ platform simplifies ADC creation by eliminating the need for enzymes or antibody sequence modifications. This approach preserves the native glycosylation profile, antibody flexibility, and covalent linkage between antibody chains, while concealing payload hydrophobicity and immunogenicity. Syndivia leverages GeminiMab™ to develop a pipeline of ADC candidates with payloads conjugated at the most clinically validated site on the antibody, allowing for higher dosing without compromising safety.
Target Audience
Syndivia's primary target audience includes pharmaceutical companies and research institutions focused on developing novel cancer therapies using antibody-drug conjugates.
Features
- Site-specific conjugation at the Cys229 hinge region of native antibodies
- Ability to achieve optimal drug-to-antibody ratios (DAR), including DAR1, DAR2, and DAR4
- Preserves native glycosylation profile, antibody flexibility, and integrity
- Conjugation site naturally conceals payload hydrophobicity and immunogenicity
- Eliminates the need for enzymes, antibody sequence modification, or specific pretargeting units
- Proprietary pipeline of ADC candidates targeting PSMA, TROP-2, Nectin-4, TF, FRα, ROR1, EGFR, c-MET, and B7-H3